Juan Pablo Melana

Prof. Juan Pablo Melana

Laboratorio de Investigaciones Bioquímicas de la Facultad de Medicina (LIBIM), Instituto de Química Básica y Aplicada del NEA, (IQUIBA NEA-UNNE-CONICET), Facultad de Medicina, Universidad Na-cional del Nordeste, 3400 Corrientes, Argentina
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in Physiologia Plantarum
Verified
Journal Article
Closed access
PDF file
LPLeandro Federico De Pedro
Leandro Federico De Pedro
FMFrancesco Mignolli
Francesco Mignolli
ASAndrea Scartazza
Andrea Scartazza
JMJuan Pablo Melana
Juan Pablo Melana
CBCarlos Alberto Bouzo
Carlos Alberto Bouzo
MVMaría Laura Vidoz
María Laura Vidoz

13 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JMJuan Pablo Melana
Juan Pablo Melana
FMFrancesco Mignolli
Francesco Mignolli
TSTania Stoyanoff
Tania Stoyanoff
MAMaría Aguirre
María Aguirre
María A. BalboaMaría A. Balboa
María A. Balboa
JRJuan Pablo Rodríguez
Juan Pablo Rodríguez
Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cell carcinoma (RCC). It is characterized by a high cell proliferation and the ability to store lipids. Previous studies have demonstrated the overexpression of enzymes associated with lipid metabolism, including stearoyl-CoA desaturase-1 (SCD-1), which increases the concentration of unsaturated fatty acids in tumor cells. In this work, we studied the expression of SCD-1 in primary ccRCC tumors, as well as in cell lines, to determine its influence on the tumor lipid composition and its role in cell proliferation. The lipidomic analyses of patient tumors showed that oleic acid (18:1n-9) is one of the major fatty acids, and it is particularly abundant in the neutral lipid fraction of the tumor core. Using a ccRCC cell line model and in vitro-generated chemical hypoxia, we show that SCD-1 is highly upregulated (up to 200-fold), and this causes an increase in the cellular level of 18:1n-9, which, in turn, accumulates in the neutral lipid fraction. The pharmacological inhibition of SCD-1 blocks 18:1n-9 synthesis and compromises the proliferation. The addition of exogenous 18:1n-9 to the cells reverses the effects of SCD-1 inhibition on cell proliferation. These data reinforce the role of SCD-1 as a possible therapeutic target.

1 May 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LFLeandro Adrian Ferrini
Leandro Adrian Ferrini
JRJuan Pablo Rodríguez
Juan Pablo Rodríguez
JMJuan Pablo Melana
Juan Pablo Melana
GOGabriela Olea
Gabriela Olea
Gonzalo Adrián OjedaGonzalo Adrián Ojeda
Gonzalo Adrián Ojeda
MAMaría Aguirre
María Aguirre